Chapter 10: Disorders of Sleep and Wakefulness and Their Treatment: Neurotransmitter Networks for Histamine and Orexin

Disorders of Sleep and Wakefulness and Their Treatment: Neurotransmitter Networks for Histamine and Orexin conceptualizes sleep and wakefulness disorders along a continuous arousal spectrum, ranging from pathologically low arousal states like excessive daytime sleepiness and hypersomnia to pathologically elevated arousal states such as insomnia and hypervigilance. The neurobiological foundation rests on the ascending reticular activating system, which maintains wakefulness through interconnected neurotransmitter networks involving histamine, dopamine, norepinephrine, serotonin, and acetylcholine. Orexin neurons in the lateral hypothalamus stabilize and coordinate these wake-promoting systems, while the ventrolateral preoptic area releases GABA to suppress arousal centers and facilitate sleep onset. Sleep-wake regulation involves two competing drives: a homeostatic component driven by adenosine accumulation during wakefulness and a circadian component controlled by the suprachiasmatic nucleus. Insomnia management employs two primary pharmacological strategies: enhancing sleep drive through GABAA positive allosteric modulators such as benzodiazepines and Z-drugs like zolpidem, or reducing excessive arousal by antagonizing wake-promoting systems. The latter includes dual orexin receptor antagonists like suvorexant and lemborexant that block orexin signaling, serotonergic hypnotics like trazodone that act on multiple receptors, and H1 receptor antagonists such as low-dose doxepin. Successful hypnotic therapy requires achieving appropriate receptor occupancy thresholds to initiate sleep while minimizing residual daytime impairment. Conversely, disorders of excessive wakefulness including narcolepsy, obstructive sleep apnea, and circadian rhythm disorders are treated by promoting arousal through dopamine and histamine enhancement. Wake-promoting agents range from classical stimulants like amphetamine and methylphenidate to adenosine antagonists like caffeine and newer compounds such as modafinil, armodafinil, and solriamfetol. Pitolisant enhances wakefulness by blocking presynaptic H3 autoreceptors to increase histamine availability, while sodium oxybate improves sleep quality and reduces cataplexy in narcolepsy through GABAB partial agonism. Circadian rhythm disorders are managed through behavioral interventions including bright light exposure and pharmacological agents like ramelteon that modulate melatonergic pathways to realign the internal biological clock.